Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 20

1.

Comparison of Prevalence and Types of Mutations in Lung Cancers Among Black and White Populations.

Campbell JD, Lathan C, Sholl L, Ducar M, Vega M, Sunkavalli A, Lin L, Hanna M, Schubert L, Thorner A, Faris N, Williams DR, Osarogiagbon RU, van Hummelen P, Meyerson M, MacConaill L.

JAMA Oncol. 2017 Jun 1;3(6):801-809. doi: 10.1001/jamaoncol.2016.6108.

2.

A bridge between academic and community radiation oncology treatment planning.

Maguire PD, Honaker G, Neal C, Meyerson M, Morris D, Rosenman J, Tepper J.

J Oncol Pract. 2007 Sep;3(5):238-41. doi: 10.1200/JOP.0752001.

3.

Response to treatment and survival of patients with non-small cell lung cancer undergoing somatic EGFR mutation testing.

Sequist LV, Joshi VA, Jänne PA, Muzikansky A, Fidias P, Meyerson M, Haber DA, Kucherlapati R, Johnson BE, Lynch TJ.

Oncologist. 2007 Jan;12(1):90-8.

PMID:
17285735
4.

Epidermal growth factor receptor mutation testing in the care of lung cancer patients.

Sequist LV, Joshi VA, Jänne PA, Bell DW, Fidias P, Lindeman NI, Louis DN, Lee JC, Mark EJ, Longtine J, Verlander P, Kucherlapati R, Meyerson M, Haber DA, Johnson BE, Lynch TJ.

Clin Cancer Res. 2006 Jul 15;12(14 Pt 2):4403s-4408s. Review.

5.

Activating mutations of the noonan syndrome-associated SHP2/PTPN11 gene in human solid tumors and adult acute myelogenous leukemia.

Bentires-Alj M, Paez JG, David FS, Keilhack H, Halmos B, Naoki K, Maris JM, Richardson A, Bardelli A, Sugarbaker DJ, Richards WG, Du J, Girard L, Minna JD, Loh ML, Fisher DE, Velculescu VE, Vogelstein B, Meyerson M, Sellers WR, Neel BG.

Cancer Res. 2004 Dec 15;64(24):8816-20.

6.

Somatic alterations in the human cancer genome.

Weir B, Zhao X, Meyerson M.

Cancer Cell. 2004 Nov;6(5):433-8. Review.

7.

Gefitinib induces apoptosis in the EGFRL858R non-small-cell lung cancer cell line H3255.

Tracy S, Mukohara T, Hansen M, Meyerson M, Johnson BE, Jänne PA.

Cancer Res. 2004 Oct 15;64(20):7241-4.

8.

Frequent HIN-1 promoter methylation and lack of expression in multiple human tumor types.

Krop I, Player A, Tablante A, Taylor-Parker M, Lahti-Domenici J, Fukuoka J, Batra SK, Papadopoulos N, Richards WG, Sugarbaker DJ, Wright RL, Shim J, Stamey TA, Sellers WR, Loda M, Meyerson M, Hruban R, Jen J, Polyak K.

Mol Cancer Res. 2004 Sep;2(9):489-94.

9.

Genomic representations using concatenates of Type IIB restriction endonuclease digestion fragments.

Tengs T, LaFramboise T, Den RB, Hayes DN, Zhang J, DebRoy S, Gentleman RC, O'Neill K, Birren B, Meyerson M.

Nucleic Acids Res. 2004 Aug 25;32(15):e121.

10.

Assessing prognosis in non-small-cell lung cancer: avenues to a more complete picture?

Dubinett SM, Elashoff D, Meyerson M.

J Clin Oncol. 2004 Aug 15;22(16):3209-11. Epub 2004 Jul 12. No abstract available.

PMID:
15249586
11.

Identifying and characterizing a novel activating mutation of the FLT3 tyrosine kinase in AML.

Jiang J, Paez JG, Lee JC, Bo R, Stone RM, DeAngelo DJ, Galinsky I, Wolpin BM, Jonasova A, Herman P, Fox EA, Boggon TJ, Eck MJ, Weisberg E, Griffin JD, Gilliland DG, Meyerson M, Sellers WR.

Blood. 2004 Sep 15;104(6):1855-8. Epub 2004 Jun 3.

12.

Genome coverage and sequence fidelity of phi29 polymerase-based multiple strand displacement whole genome amplification.

Paez JG, Lin M, Beroukhim R, Lee JC, Zhao X, Richter DJ, Gabriel S, Herman P, Sasaki H, Altshuler D, Li C, Meyerson M, Sellers WR.

Nucleic Acids Res. 2004 May 18;32(9):e71.

13.

An integrated view of copy number and allelic alterations in the cancer genome using single nucleotide polymorphism arrays.

Zhao X, Li C, Paez JG, Chin K, Jänne PA, Chen TH, Girard L, Minna J, Christiani D, Leo C, Gray JW, Sellers WR, Meyerson M.

Cancer Res. 2004 May 1;64(9):3060-71.

14.

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.

Paez JG, Jänne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, Naoki K, Sasaki H, Fujii Y, Eck MJ, Sellers WR, Johnson BE, Meyerson M.

Science. 2004 Jun 4;304(5676):1497-500. Epub 2004 Apr 29.

15.

High-resolution single-nucleotide polymorphism array and clustering analysis of loss of heterozygosity in human lung cancer cell lines.

Jänne PA, Li C, Zhao X, Girard L, Chen TH, Minna J, Christiani DC, Johnson BE, Meyerson M.

Oncogene. 2004 Apr 8;23(15):2716-26.

PMID:
15048096
16.

Menin associates with a trithorax family histone methyltransferase complex and with the hoxc8 locus.

Hughes CM, Rozenblatt-Rosen O, Milne TA, Copeland TD, Levine SS, Lee JC, Hayes DN, Shanmugam KS, Bhattacharjee A, Biondi CA, Kay GF, Hayward NK, Hess JL, Meyerson M.

Mol Cell. 2004 Feb 27;13(4):587-97.

17.

Molecular classification and molecular genetics of human lung cancers.

Meyerson M, Franklin WA, Kelley MJ.

Semin Oncol. 2004 Feb;31(1 Suppl 1):4-19. Review.

PMID:
14981576
18.

Toxic cure: Hyperfractionated radiotherapy with concurrent cisplatin and fluorouracil for Stage III and IVA head-and-neck cancer in the community.

Maguire PD, Meyerson MB, Neal CR, Hamann MS, Bost AL, Anagnost JW, Ungaro PC, Pollock HD, McMurray JE, Wilson EP, Kotwall CA.

Int J Radiat Oncol Biol Phys. 2004 Mar 1;58(3):698-704.

PMID:
14967423
19.

Short interfering RNAs can induce unexpected and divergent changes in the levels of untargeted proteins in mammalian cells.

Scacheri PC, Rozenblatt-Rosen O, Caplen NJ, Wolfsberg TG, Umayam L, Lee JC, Hughes CM, Shanmugam KS, Bhattacharjee A, Meyerson M, Collins FS.

Proc Natl Acad Sci U S A. 2004 Feb 17;101(7):1892-7. Epub 2004 Feb 9.

20.

Loss of heterozygosity and its correlation with expression profiles in subclasses of invasive breast cancers.

Wang ZC, Lin M, Wei LJ, Li C, Miron A, Lodeiro G, Harris L, Ramaswamy S, Tanenbaum DM, Meyerson M, Iglehart JD, Richardson A.

Cancer Res. 2004 Jan 1;64(1):64-71.

Supplemental Content

Loading ...
Support Center